JUMPCODE Genomics
San Diego, US · Founded 2016 · Delaware corporation · 7 employees on LinkedIn · 4 known investors
Find your way into JUMPCODE Genomics
Sign up to see every warm intro you have to JUMPCODE Genomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the JUMPCODE Genomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.
Founders & leadership

Board

Investors · 4
How we know: Arboretum Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Baird Capital's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$38.7M disclosed across 5 rounds · 2018–2024
▶$3.5MraisedAug 2024 · 8 investors · BiotechnologyRule 506(b)
- David Michael SalterExecutive Officer, Director
- Court TurnerDirector
- Joseph LeeDirector
- Offering amount
- $11.5M
- Amount sold
- $3.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.2MraisedMay 2023 · 7 investors · BiotechnologyRule 506(b)
- Yaron HakakExecutive Officer, Director
- Frank WitneyDirector
- Court TurnerDirector
- Kirk MalloyDirector
- Dan KidleDirector
- Brandon PoeExecutive Officer
- Offering amount
- $16.1M
- Amount sold
- $9.2M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedDec 2020 · 5 investors · BiotechnologyRule 506(b)
- Keith BrownExecutive Officer
- Yaron HakakExecutive Officer, Director
- Dan KidleDirector
- Kirk MalloyDirector
- Kevin LiDirector
- Frank WitneyDirector
- Michael LiangDirector
- Offering amount
- $21M
- Amount sold
- $21M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2020 · 1 investors · BiotechnologyRule 506(b)
- Keith BrownExecutive Officer, Director
- Eugene ChenDirector
- Kevin LiDirector
- Joel RotroffDirector
- Kirk MalloyDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.5MraisedSep 2018 · 4 investors · OtherRule 506(b)
- Eugene ChenDirector
- Keith BrownExecutive Officer, Director
- Joel RotroffDirector
- Kirk MalloyDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through JUMPCODE Genomics went on to found or lead other companies.
Related companies · 4
Companies working in the same space as JUMPCODE Genomics.
Frequently asked questions
- What does JUMPCODE Genomics do?
- Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.
- Who are JUMPCODE Genomics's investors?
- JUMPCODE Genomics's investors include Arboretum Ventures, Baird Capital, Global Health Investment Corporation, LYZZ Capital.
- How much funding has JUMPCODE Genomics raised?
- JUMPCODE Genomics has disclosed $38.7M raised across 5 rounds.
- Where is JUMPCODE Genomics headquartered?
- JUMPCODE Genomics is headquartered in San Diego, US.







